Mixed Q1 for Penumbra: Revenue Up 15.6% to $374.76M, EPS Down to $0.82
PEN sits 47% above its 52-week low of $221.26.
Summary
Penumbra Inc. reported its first-quarter 2026 results, showing a 15.6% year-over-year increase in revenue to $374.76 million. However, diluted earnings per share (EPS) declined 18% to $0.82, and net income also fell. This earnings report comes as Penumbra is under a definitive merger agreement to be acquired by Boston Scientific for approximately $14.5 billion, or $374 per share, a deal confirmed in its recent 10-K filing and reiterated in subsequent SEC filings. While the company's stock price is largely influenced by the pending acquisition, these results provide an update on the operational health of the business prior to the deal's expected close. The mixed performance, with strong revenue growth but declining profitability, might be noted by M&A arbitrageurs but is unlikely to significantly alter the deal's trajectory unless it signals a material adverse change. Traders will continue to monitor progress on the Boston Scientific acquisition, including regulatory approvals and closing conditions, as this remains the primary driver for the stock.
At the time of this announcement, PEN was trading at $324.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $221.26 to $362.41. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.